What's in Gustave Roussy, Cancer Campus, Grand Paris's pipeline?

Gustave Roussy, Cancer Campus, Grand Paris has 41 drugs in our index: 2 marketed, 0 filed, 14 in Phase 3, 13 in Phase 2, 12 in Phase 1.

Which companies overlap with Gustave Roussy, Cancer Campus, Grand Paris's portfolio?

Top competitors by shared drug class: M.D. Anderson Cancer Center, Assistance Publique - Hôpitaux de Paris, AstraZeneca, Jiangsu HengRui Medicine Co., Ltd., Pfizer.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/gustave-roussy-cancer-campus-grand-paris.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Gustave Roussy, Cancer Campus, Grand Paris — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Gustave Roussy, Cancer Campus, Grand Paris pipeline: 2 marketed, 0 filed, 14 Phase 3, 13 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 14 Phase 3 13 Phase 2 12 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
rhTSH	rhTSH	marketed	Recombinant hormone	TSH receptor (TSHR)	Oncology; Endocrinology
Vistide	Vistide	marketed		DNA polymerase catalytic subunit	Immunology
LMB C	LMB C	phase 3	Immunotoxin	CD25 (IL-2 receptor alpha chain)	Oncology
LMB B	LMB B	phase 3	Immunotoxin	CD25 (IL-2 receptor alpha chain)	Oncology
Doxorubicin, Methotrexate	Doxorubicin, Methotrexate	phase 3	Chemotherapy combination (anthracycline + antimetabolite)	Topoisomerase II (doxorubicin); Dihydrofolate reductase (methotrexate)	Oncology
doxorubicin, ifosfamide, cisplatin	doxorubicin, ifosfamide, cisplatin	phase 3	anthracycline antibiotic, alkylating agent, platinum-based alkylating agent		Oncology
without COPADM3	without COPADM3	phase 3
mini CYVE, without 3 maintenance courses	mini CYVE, without 3 maintenance courses	phase 3	CD47/SIRPα inhibitor	CD47	Oncology
Genomic driven chemotherapy	Genomic driven chemotherapy	phase 3			Oncology
Isolated pelvis perfusion	Isolated pelvis perfusion	phase 3			Oncology
Thromboprophylaxis	Thromboprophylaxis	phase 3			Cardiovascular
Etoposide, Ifosfamide, Methotrexate	Etoposide, Ifosfamide, Methotrexate	phase 3	Combination chemotherapy (topoisomerase II inhibitor, alkylating agent, antimetabolite)	DNA (topoisomerase II, DNA alkylation, dihydrofolate reductase)	Oncology

Therapeutic area mix

Oncology · 15
Other · 2
Cardiovascular · 1
Immunology · 1
Oncology; Endocrinology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

M.D. Anderson Cancer Center · 2 shared drug classes
Assistance Publique - Hôpitaux de Paris · 2 shared drug classes
AstraZeneca · 2 shared drug classes
Jiangsu HengRui Medicine Co., Ltd. · 2 shared drug classes
Pfizer · 2 shared drug classes
Sun Yat-sen University · 2 shared drug classes
Ascletis Pharmaceuticals Co., Ltd. · 1 shared drug class
Asahi Kasei Pharma Corporation · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Gustave Roussy, Cancer Campus, Grand Paris:

Cite this brief

Drug Landscape (2026). Gustave Roussy, Cancer Campus, Grand Paris — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/gustave-roussy-cancer-campus-grand-paris. Accessed 2026-05-17.